The $80M Bet That Superbugs Will Make Antibiotics Cool Again
A Suzhou biotech just raised $80 million on the Hong Kong Stock Exchange to fight bacterial infections, an area most investors won't touch. Its lead drug crushed the standard of care for H. pylori in Phase III, and the company's hybrid chemistry platform could reshape how we treat everything from stomach bugs to infected hip implants.
Half the world has a stomach infection it doesn't know about. The bacterium Helicobacter pylori lives inside roughly 44% of the global population, quietly raising the risk of ulcers and gastric cancer. Treating it used to be straightforward: you'd throw a cocktail of antibiotics at it and move on. But the bugs are fighting back, and the old cocktails are failing at alarming rates.
That's the backdrop for TenNor Therapeutics, a Suzhou-based biotech that just pulled off something rare: it convinced investors to put ~$80 million into a company built around fighting bacterial infections. The company listed on the Hong Kong Stock Exchange on May 22, 2026, trading under ticker 6872.HK, in what might be the most interesting anti-infective IPO in years.
Why Antibiotics Are the Ugly Duckling of Biotech
If you're a biotech founder, you probably want to work in oncology. That's where the money is, where the valuations soar, where investors throw cash at anything with "immuno" in the name. Anti-infectives? They're the responsible, unglamorous cousin nobody invites to the party.
The economics are brutal. You spend years developing a new antibiotic, finally get it approved, and then doctors are told not to prescribe it widely (because overuse breeds resistance). It's like opening a restaurant where the health inspector tells customers to eat there as little as possible. Several antibiotic companies have gone bankrupt in recent years despite having FDA-approved products on the market.
So when TenNor raises $80 million in a public offering for an anti-infective pipeline, it's worth paying attention. Either the market sees something different here, or Hong Kong investors are feeling particularly adventurous.
The Deal at a Glance
TenNor offered 8.28 million H shares at HKD 75.70 each, pulling in gross proceeds of about HKD 627 million (roughly USD 80 million). The deal included a 15% overallotment option, meaning underwriters could sell additional shares if demand warranted it.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
CITIC Securities (Hong Kong) and ABCI Capital served as joint sponsors. That's a credible pairing: CITIC has been on a tear in Hong Kong's biotech IPO market, sponsoring roughly one-third of IPO applicants on the exchange as of late 2025. Their biggest recent biotech deal was GenFleet Therapeutics, which raised about $233 million in what became the largest Chapter 18A biotech listing since 2022.
TenNor's $80 million is more modest, but it's a meaningful raise for a company in a therapeutic area that most investors instinctively avoid.
The net proceeds (after fees and expenses) came to about HKD 558 million, earmarked for R&D, regulatory filings, manufacturing, and eventually commercialization. In other words: finish building the drugs, get them approved, and start selling them.
The Drug That Could Rewrite H. Pylori Treatment
TenNor's crown jewel is rifasutenizol (known internally as TNP-2198), and understanding it requires a quick detour into how current H. pylori treatment works.
Right now, the standard approach is "bismuth quadruple therapy," a four-drug regimen that sounds about as pleasant as it is. Patients take a proton pump inhibitor, bismuth, and two antibiotics for 14 days. It works reasonably well when the bacteria cooperate, but resistance rates to key antibiotics in the regimen (particularly clarithromycin and metronidazole) have been climbing worldwide.
Rifasutenizol is a hybrid molecule, a conjugate that combines two mechanisms into one drug. One half works like a rifamycin (blocking the bacterium's ability to make RNA), while the other half acts like a nitroimidazole (damaging the DNA of anaerobic organisms). Think of it as a molecular Swiss Army knife designed to attack the bug from two angles simultaneously.
The results from TenNor's Phase III trial in China were genuinely impressive. A simpler, three-drug regimen built around rifasutenizol achieved over 90% eradication of H. pylori, and it beat the standard bismuth quadruple therapy on the primary endpoint. Fewer drugs, better results. That's the kind of data that gets gastroenterologists excited.
TenNor submitted a New Drug Application (NDA) to China's NMPA (the country's drug regulator) in August 2025 and has already obtained a Class B manufacturing license. Translation: the factory is ready; they're waiting for the green light to start producing.
In the U.S., the story is earlier but promising. The FDA granted rifasutenizol both QIDP designation (Qualified Infectious Disease Product, which comes with extra market exclusivity) and Fast Track status for H. pylori. Those aren't rubber stamps; they signal that the FDA sees unmet medical need and is willing to expedite the review process.
Beyond the Stomach: A Broader Arsenal
Rifasutenizol for H. pylori is the headliner, but TenNor isn't a one-trick pony. Their second major platform is rifaquizinone (TNP-2092), another hybrid molecule aimed at a completely different set of problems.
The intravenous version is in Phase III trials in China for acute bacterial skin and skin structure infections. If you've ever had a hip replacement or a knee implant, this is relevant: bacteria can form biofilms on these devices (think of it as microscopic armor plating), making infections extraordinarily difficult to treat. The IV formulation already completed a positive Phase II trial against vancomycin for skin infections, and the FDA granted it Orphan Drug designation for prosthetic joint infections.
There's also an oral version targeting gut-related conditions like hepatic encephalopathy (a brain fog condition caused by liver cirrhosis, where gut bacteria produce too much ammonia). That program has completed Phase II with positive results.
Across all formulations and indications, the company claims seven innovative assets in its pipeline.
It's a smart portfolio strategy. Instead of one molecule for one disease, TenNor has built a platform around its hybrid chemistry and is deploying it across multiple routes of administration and clinical settings. That "portfolio breadth" story is exactly what Hong Kong investors want to hear from anti-infective companies, because it reduces the risk of the entire business hinging on a single approval.
The Timing Is Better Than You'd Think
TenNor picked a good window to go public. Hong Kong's biotech capital markets have been on a serious rebound after years of what the industry called "biology winter." By the end of Q3 2025, the exchange had seen $23.9 billion raised across 66 IPOs, a 192% jump from the prior year.
For pre-revenue biotechs, Hong Kong's Chapter 18A listing regime has been the key on-ramp. By early 2026, 84 companies had listed through this pathway, which allows clinical-stage biotechs without revenue to access public markets. TenNor used this same regime.
But there's an important caveat: the pipeline is getting crowded. As of 31 March 2026, 366 companies were in various stages of the listing queue, with 73 Chinese pharma and biotech firms having filed for Hong Kong IPOs in 2025 alone. Standing out matters more than ever.
From Abbott Labs to Suzhou Startup
TenNor was founded in 2013 by Dr. Zhenkun Ma, a medicinal chemist with stints at Abbott and the TB Alliance. The company's origin story has an interesting twist: its core intellectual property came from a patent transfer from Cumbre Inc., where Ma had previously served as Director of Medicinal Chemistry. Those composition-of-matter patents formed the foundation for both rifasutenizol and rifaquizinone.
The funding journey tells the classic biotech escalation story. Series A raised $7 million in 2013. Series B brought in $25 million in 2016, backed by Northern Light Venture Capital. By 2024, the company closed a Series E round of over 300 million RMB (roughly $40 to $45 million), with a notable new backer: the AMR Action Fund, a global fund specifically dedicated to fighting antimicrobial resistance.
That last investor is significant. The AMR Action Fund was created by more than 20 pharmaceutical companies to invest in late-stage antibiotics developers. When they write a check, it's a signal that the science is credible and the commercial path is plausible.
The Big Question Nobody's Asking
TenNor's IPO is a success story on its surface. Good data, credible investors, smart timing, and a real medical need. But the uncomfortable question lurking beneath every anti-infective investment remains: can you actually make money selling antibiotics?
The graveyard of antibiotic companies that had great drugs but terrible businesses is well documented. Achaogen went bankrupt a year after the FDA approved its antibiotic. Melinta needed restructuring. The pattern is familiar enough to make any investor nervous.
TenNor's counterargument comes in a few parts. First, H. pylori is a massive market (hundreds of millions of potential patients globally), and unlike hospital antibiotics, treatment doesn't face the same stewardship restrictions that limit prescribing. Second, their China-first strategy plays to a market where H. pylori prevalence is particularly high and the healthcare system is actively looking for better treatment options. Third, the multi-indication portfolio spreads the risk beyond a single product.
Whether that's enough to break the antibiotic curse is an open question. But $80 million says at least some investors think it's worth the bet.
In a market flooded with oncology me-toos and autoimmune look-alikes, a company swinging at one of medicine's oldest enemies with genuinely new chemistry is, at minimum, refreshing. The superbugs are winning. TenNor thinks it has an answer. Now it has the cash to prove it.
Clinical & Regulatory5 min read
A Billion-Dollar Bet on Parkinson's Just Went Up in Smoke
Biogen and Denali's LRRK2 inhibitor nailed every biological target in a 648-patient Parkinson's trial, then failed to help a single clinical measure. A billion-dollar partnership just lost its centerpiece, and the implications ripple across the entire field of neurodegeneration.
